We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Sacubitril/valsartan in peritoneal dialysis—lessons from a pharmacokinetic study.
- Authors
Judge, Parminder K; Herrington, William G; Haynes, Richard
- Abstract
However, dialysis patients have usually been excluded from trials of HF therapies, including trials of treatments targeting the natriuretic peptide system. Twenty-six (65%) patients received SV 100 mg BD, 6 (15%) received SV 100 mg OD and 8 (20%) received SV 50 mg BD [[9]]. Patients with chronic kidney disease (CKD) are at increased risk of progression to kidney failure and cardiovascular events [[1]].
- Subjects
PERITONEAL dialysis; VALSARTAN; ANGIOTENSIN-receptor blockers; BRAIN natriuretic factor; ENTRESTO; LIQUID chromatography-mass spectrometry
- Publication
Nephrology Dialysis Transplantation, 2023, Vol 38, Issue 8, p1780
- ISSN
0931-0509
- Publication type
Article
- DOI
10.1093/ndt/gfad066